JUMBO Trial: Joint Utilization of Medications to Block Platelets Optimally
Study of:
Study drug (CS-747) vs. clopidogrel; sponsored by Eli Lilly and Company
This trial is designed to test the safety of increasing doses of a new drug (CS-747) and to compare it to a stadard regimen of clopidogrel. Patients are followed through their hospital stay and at 35 days following their procedure. This trial is designed to test the safety of increasing doses of a new drug (CS-747) and to compare it to a standard regimen of clopidogrel. Patients are followed through their hospital stay and at 35 days following their procedure.
- M. Nicholas Burke, MD
- Ivan J. Chavez, MD, FACC
- Timothy D. Henry, MD, FACC
- John R. Lesser, MD, FACC
- Daniel Lips, MD, FACC
- Michael R. Mooney, MD, FACC
- Wesley R. Pedersen, MD, FACC
- Anil K. Poulose, MD, FACC
- Jay H. Traverse, MD, FACC, FAHA
- Yale Wang, MD, FACC, FSCAI
For more information about the interventional cardiology research program at the Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, please contact Carol Stone at 612-863-9124. |